EMC Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

EMC Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$38K	Hold	700	–	–	0.02%	262
2025 Q3	$45K	Hold	700	–	–	0.02%	267
2025 Q2	$34K	Sell	700 -800	-53%	-$31K	0.02%	275
2025 Q1	$51K	Sell	1,500 -2,000	-57%	-$84.8K	0.03%	255
2024 Q4	$138K	Buy	3,500 +170	+5%	+$8.03K	0.08%	201
2024 Q3	$216K	Sell	3,330 -5,970	-64%	-$303K	0.14%	148
2024 Q2	$496K	Buy	9,300 +8,300	+830%	+$480K	0.29%	38
2024 Q1	$66K	Buy	+1,000	New	+$71.6K	0.04%	258

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EMC Capital Management's CRSP Position: Q4 2025 in Review

EMC Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q4 2025 at 700 shares worth $38K. The position accounts for 0.02% of the portfolio, ranked #262.

EMC Capital Management first reported a position in CRSP in Q1 2024 and has held it in 8 quarters since. The position peaked at $496K in Q2 2024. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

EMC Capital Management held 700 shares of CRISPR Therapeutics worth $38K as of Q4 2025.
EMC Capital Management left its CRISPR Therapeutics share count unchanged in Q4 2025.
CRISPR Therapeutics made up 0.02% of EMC Capital Management's portfolio in Q4 2025, its #262 holding.
EMC Capital Management first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 8 quarters since.
EMC Capital Management's CRISPR Therapeutics position peaked at $496K in Q2 2024.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on EMC Capital Management's 13F filing for Q4 2025, filed 9 Mar 2026.